0.48
-0.0236(-4.68%)
Currency In USD
| Previous Close | 0.5 |
| Open | 0.48 |
| Day High | 0.5 |
| Day Low | 0.47 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.25 |
| Volume | 1.46M |
| Average Volume | 3.27M |
| Market Cap | 14.54M |
| PE | -0.13 |
| EPS | -3.7 |
| Moving Average 50 Days | 0.49 |
| Moving Average 200 Days | 0.86 |
| Change | -0.02 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.67 as of October 21, 2025 at a share price of $0.481. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $6.93 as of October 21, 2025 at a share price of $0.481.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
GlobeNewswire Inc.
Sep 25, 2025 12:35 PM GMT
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections,
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
GlobeNewswire Inc.
Sep 09, 2025 12:45 PM GMT
European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjects by end of September On track to recruit to 45
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
GlobeNewswire Inc.
Sep 08, 2025 12:30 PM GMT
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”),